MAGEC2 Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
MAGEC2 Peptide Applications :
Blocking Background :
MAGE-C2/C3 (Melanoma-associated antigen C2, Hepatocellular carcinoma-associated antigen 587) is a 373 amino acid protein encoded by the human gene MAGEC2. Genes of the MAGE family direct the expression of tumor antigens that are recognized on human melanomas by autologous cytolytic T lymphocytes. Among tumor tissues, MAGE-C2/C3 is frequently expressed in seminomas, melanomas, and bladder transitional cell carcinomas. It is also expressed in a significant fraction of head and neck carcinomas, breast carcinomas, nonsmall-cell lung carcinomas, and sarcomas. In hepatocellular carcinoma, there is a inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression. MAGE-C2/C3 is not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. It is strongly expressed in spermatogonia and primary spermatocytes, however, at later stages of maturation, expression gradually decreases to become undetectable in mature spermatids. Alternative Name :
Melanoma-associated antigen C2; Cancer/testis antigen 10; CT10; Hepatocellular carcinoma-associated antigen 587; MAGE-C2 antigen; MAGE-E1 antigen; MAGE-C2; HCA587; MAGEE1 Swiss-Prot :
Q9UBF1 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide MAGEC2. (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS5956 MAGEC2 pAb.
MAGEC2 Peptide Applications :
Blocking Background :
MAGE-C2/C3 (Melanoma-associated antigen C2, Hepatocellular carcinoma-associated antigen 587) is a 373 amino acid protein encoded by the human gene MAGEC2. Genes of the MAGE family direct the expression of tumor antigens that are recognized on human melanomas by autologous cytolytic T lymphocytes. Among tumor tissues, MAGE-C2/C3 is frequently expressed in seminomas, melanomas, and bladder transitional cell carcinomas. It is also expressed in a significant fraction of head and neck carcinomas, breast carcinomas, nonsmall-cell lung carcinomas, and sarcomas. In hepatocellular carcinoma, there is a inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression. MAGE-C2/C3 is not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. It is strongly expressed in spermatogonia and primary spermatocytes, however, at later stages of maturation, expression gradually decreases to become undetectable in mature spermatids. Alternative Name :
Melanoma-associated antigen C2; Cancer/testis antigen 10; CT10; Hepatocellular carcinoma-associated antigen 587; MAGE-C2 antigen; MAGE-E1 antigen; MAGE-C2; HCA587; MAGEE1 Swiss-Prot :
Q9UBF1 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide MAGEC2. (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS5956 MAGEC2 pAb.
Blocking peptide available as BS5956PP